• TRPV1+ Nerve Stimulation Suppresses Systemic Inflammation vi

  2026-07-27

  Song et al. (2025) uncover that targeted stimulation of TRPV1+ peripheral somatosensory nerves at the nape induces rapid, systemic anti-inflammatory effects via neural reflex circuits that drive both sympathetic and parasympathetic pathways. This mechanistic insight advances our understanding of neuro-immune interfaces and offers a foundation for novel, region-specific interventions in inflammatory disease.

• Enhanced mTOR Inhibitor Discovery Using Drug-Sensitized Yeas

  2026-07-26

  Breen et al. introduce a robust yeast-based system for the sensitive detection of mTOR pathway inhibitors, enabling a 200–250-fold increase in detection sensitivity for established molecules. Their platform provides a rapid, cost-effective means to screen for TOR inhibitors, clarifying the specificity of compounds like Canagliflozin in metabolic research.

• Dexamethasone (DHAP): Precision Modulation of NF-κB in Advan

  2026-07-25

  Explore how dexamethasone, a leading glucocorticoid anti-inflammatory, enables nuanced control of NF-κB signaling in immune and stem cell models. This article reveals practical assay insights, advanced parameterization, and evidence-driven guidance for translational inflammation research.

• GOT1 Inhibition Reshapes Glutamine Metabolism in Pancreatic

  2026-07-24

  The reference study uncovers ziprasidone as a novel, non-competitive inhibitor of GOT1, demonstrating its ability to disrupt glutamine metabolism and redox homeostasis in pancreatic ductal adenocarcinoma (PDAC) cells. These findings highlight a promising metabolic vulnerability for therapeutic intervention and provide a framework for studying redox and metabolic regulation in cancer models.

• 5-Methyl-CTP: Enhancing mRNA Synthesis for Stability & Effic

  2026-07-24

  5-Methyl-CTP brings a transformative edge to mRNA synthesis workflows with its unique methyl modification, closely mimicking native RNA methylation for superior transcript stability and translation efficiency. This enables researchers to accelerate the development of robust mRNA vaccines and therapeutics, as exemplified in the latest advances in dairy cow influenza vaccine models.

• Cannabidiol Modulates Orofacial Inflammatory Pain via Endoca

  2026-07-23

  This study elucidates how cannabidiol (CBD) mitigates both sensory and affective dimensions of orofacial inflammatory pain in mice, revealing distinct peripheral and central mechanisms involving the endocannabinoid system. The findings highlight the translational potential of CBD for comprehensive pain management, with implications for targeted cannabinoid receptor research.

• Patient-Derived Gastric Cancer Assembloids Illuminate Drug R

  2026-07-23

  This study introduces a patient-matched gastric cancer assembloid model that integrates tumor organoids with autologous stromal cell subpopulations, recapitulating the cellular complexity of primary tumors. The model reveals how stromal components influence gene expression and modulate therapeutic sensitivity, offering a more predictive platform for preclinical drug testing and personalized medicine.

• FLOT1-FOSL2-EphA2 Axis Drives Microglial Polarization in Alz

  2026-07-22

  This study identifies the FLOT1-FOSL2 interaction as a key driver of EphA2-mediated pro-inflammatory microglial polarization via p38/MAPK signaling in Alzheimer's disease. The findings offer mechanistic insight into neuroinflammation and highlight a potential therapeutic target to modulate cognitive decline in neurodegenerative disease models.

• Oligomycin A: Illuminating Mitochondrial Control in Tumor Im

  2026-07-22

  Explore how Oligomycin A, a mitochondrial ATP synthase inhibitor, enables researchers to dissect immunometabolic crosstalk and metabolic reprogramming in cancer. This article uniquely integrates the latest mechanistic insights and practical assay strategies for advanced mitochondrial bioenergetics research.

• DiscoveryProbe Natural Product Library Plus in Antiparasitic

  2026-07-21

  The DiscoveryProbe Natural Product Library Plus enables rapid, high-content screening of cell-permeable bioactive compounds to accelerate antiparasitic drug discovery. Its pre-dissolved, quality-validated format supports reliable identification of potent inhibitors, exemplified by recent breakthroughs in targeting Cryptosporidium parvum.

• Epinephrine Bitartrate: Advanced Protocols in Adrenergic Res

  2026-07-21

  (-)-Epinephrine (+)-bitartrate empowers researchers to precisely modulate adrenergic signaling in cardiovascular, neurobiology, and translational studies. This guide covers optimized workflows, troubleshooting, and the latest comparative insights for this non-selective adrenergic receptor agonist.

• Lenalidomide (CC-5013): Protocol Advances in Myeloma Researc

  2026-07-20

  Lenalidomide (CC-5013) from APExBIO is a versatile immune system activation agent and angiogenesis inhibitor, empowering reliable myeloma and hematologic malignancy research. This article bridges new epigenetic insights with actionable, troubleshooting-focused workflows for reproducible, high-impact experiments.

• YTHDF1 Phase Separation Drives SSC Fate via IkB-NF-kB-CCND1

  2026-07-20

  Fang et al. reveal that liquid-liquid phase separation (LLPS) of the m6A reader YTHDF1 is essential for the direct transdifferentiation of spermatogonial stem cells (SSCs) to neural stem cell-like cells, acting through selective inhibition of IkBa/b mRNA translation and activation of the IkB-NF-kB-CCND1 pathway. This mechanistic insight into protein-RNA condensates expands our understanding of cell fate transitions and offers a platform for translational research in neurobiology and regenerative medicine.

• Verapamil ((±)-Verapamil) in Hypoxia-Driven Inflammation Mod

  2026-07-19

  Verapamil ((±)-Verapamil) offers unmatched precision in dissecting the ROS/TXNIP/NLRP3 axis during hypoxia-induced inflammation. This guide translates the latest mechanistic discoveries and experimental benchmarks into actionable protocols and troubleshooting strategies—empowering researchers with APExBIO's high-purity, reliable reagent.

• TRIB3 Knockdown Sensitizes ccRCC to Sunitinib via Ferroptosi

  2026-07-18

  This study demonstrates that silencing TRIB3 enhances the effectiveness of the multi-targeted RTK inhibitor sunitinib in clear cell renal cell carcinoma (ccRCC) by promoting ferroptosis through the SLC7A11/GPX4 pathway. The findings provide mechanistic insight into overcoming sunitinib resistance in ccRCC and suggest new directions for therapeutic strategies.

450 records 10/30 page Previous Next First page 上5页 678910 下5页 Last page